Apexian Pharmaceuticals, an Indiana-based clinical stage biotechnology company developing novel compounds to treat cancer, closed a Series A financing round.
The amount of the round was not disclosed.
Elevate Ventures, a venture development organization based in Indiana, committed the funding through their Indiana 21st Century Research & Technology Fund.
Led by President and Chief Executive Officer Steve Carchedi, Apexian Pharmaceuticals is a clinical-stage biotechnology company focused on developing safe and effective therapy for patients. Its lead drug candidate APX3330, is an oral first-in-class novel inhibitor of the APE1 protein, a critical node in cancer cell signaling.
The company intends to use the funds to initiate their phase 1 clinical study for APX3330.